Amphivena Therapeutics |

09 Dec Amphivena Reports Data on Phase 1 Study of AMV564 at ASH Annual Meeting

Posted at 10:36h in Press Releases, Press Releases 2019

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text] South San Francisco, CA – (Business Wire) -- Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, presented today at the American Society of Hematology annual meeting data from a Phase...

02 Dec Amphivena Appoints Dr. Curtis L. Ruegg as President and Chief Executive Officer

Posted at 07:00h in Press Releases, Press Releases 2019

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text] South San Francisco, CA – December 2, 2019 -- Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, said today that Curtis L. Ruegg, Ph.D. will join the company as its...

07 Nov Rationale for Expansion of AMV564 into Solid Tumors

Posted at 11:59h in Press Releases, Press Releases 2019

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text] Selectivity of AMV564 Presents Opportunity in Patients with Solid Tumors South San Francisco, CA – November 7, 2019 -- Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, will present at...

16 Oct Amphivena Initiates Solid Tumor Clinical Trial

Posted at 08:58h in Press Releases, Press Releases 2019

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text] Amphivena to advance AMV564 in a Multi-Center Dose Finding Phase 1 Clinical Study in Patients with Solid Tumors South San Francisco, CA -- October 16, 2019 -- Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell...

01 Jul Amphivena’s Human Proof-of-Concept Data for AMV564 in Relapsed/Refractory AML Updated at the European Hematology Association Annual Meeting

Posted at 08:00h in Press Releases, Press Releases 2019

South San Francisco, CA – July 1, 2019 -- Amphivena Therapeutics, Inc., highlighted initial data from the dose escalation portion of the First-in-Human Phase 1 trial evaluating AMV564 in patients with relapsed or refractory acute myeloid leukemia (AML, AMV564-101, NCT03144245) in an oral presentation June...

05 Mar Amphivena Expands Executive Team – Victoria Smith, Ph.D. Named Chief Scientific Officer; Peter Van Vlasselaer, Ph.D. Appointed Executive Chairman of the Board

Posted at 21:57h in Press Releases, Press Releases 2019

[fluid][html css="margin-top:23px;"] SOUTH SAN FRANCISCO – March 5, 2019 -- Amphivena Therapeutics, Inc., a privately held clinical stage immuno-oncology (I/O) company that develops T cell engager therapeutics for myeloid malignancies and solid tumors, announced today the appointment of Victoria Smith, Ph.D. to the position of Chief...